Maplight Therapeutics, Inc.’s (NASDAQ:MPLT) Quiet Period To End on December 8th

Maplight Therapeutics’ (NASDAQ:MPLT) quiet period is set to end on Monday, December 8th. Maplight Therapeutics had issued 14,750,000 shares in its public offering on October 27th. The total size of the offering was $250,750,000 based on an initial share price of $17.00. During Maplight Therapeutics’ quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 price objective for the company. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Stifel Nicolaus started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock. Morgan Stanley started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $32.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

Maplight Therapeutics Stock Up 4.9%

Shares of NASDAQ:MPLT opened at $13.63 on Monday. Maplight Therapeutics has a 1 year low of $12.24 and a 1 year high of $20.86.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.